SCHEMBL275514

SCHEMBL275514

CCCc1ccnc2ccc3ccccc3c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.46
ATM Q13315 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
LOXL2 Q9Y4K0 1/20 0.41
GAA P10253 1/20 0.41
CYP2A6 P11509 1/20 0.40
CYP2D6 P10635 1/20 0.38
HIF1A Q16665 1/20 0.38
MAPT P10636 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TYMS P04818 1/20 0.38
LMNA P02545 3/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
AHR P35869 1/20 0.36
F12 P00748 1/20 0.36
PLAU P00749 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5143767 0.90 CYP3A4 (0.42) CYP3A4ATMKDM4EALDH1A1HPGD
SCHEMBL10976790 0.78 KDM4E (0.49) ATMKDM4EALDH1A1HPGDGAA
SCHEMBL528996 0.78 LOXL2 (0.60) CYP3A4KDM4EALDH1A1HPGDLOXL2
SCHEMBL27670163 0.77 CYP3A4 (0.45) CYP3A4KDM4EALDH1A1HPGDLOXL2
Bromide SCHEMBL7457488 0.76 LOXL2 (0.58) CYP3A4KDM4EALDH1A1HPGDLOXL2
Iodide SCHEMBL1343657 0.76 LOXL2 (0.58) CYP3A4KDM4EALDH1A1HPGDLOXL2
SCHEMBL7058871 0.75 CYP3A4 (0.53) CYP3A4ATMKDM4EALDH1A1HPGD
SCHEMBL24170711 0.72 ELANE (0.40) LOXL2NOS2ELANE
SCHEMBL6321346 0.70 CYP3A4 (0.52) CYP3A4KDM4EALDH1A1HPGDGAA
SCHEMBL5139016 0.70 CYP3A4 (0.52) CYP3A4ATMKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43244-E1 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use H. LUNDBECK A/S (DK) 2012-03-13 US disclosed
US-RE42802-E1 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use H. LUNDBECK A/S (DK) 2011-10-04 US disclosed
US-6998405-B2 Parkinson's and Huntington's disease; psychoses, impotence, renal or heart failure, schizophrenia H. LUNDBECK A/S (DK) 2006-02-14 US disclosed
US-6683087-B2 TREATMENT OF PARKINSON'S DISEASE, PSYCHOSES, HUNTINGTON'S DISEASE, IMPOTENCE, RENAL FAILURE, HEART FAILURE OR HYPERTENSION AXON BIOCHEMICALS B.V. (NL) 2004-01-27 US disclosed
US-20030087948-A1 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use H. LUNDBECK A/S (DK) 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087948-A1 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use ADRA1D, ABCE1, ADRA1B CYP3A4 633/4885ATM 3499/4885KDM4E 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.